Cancer immunotherapy strategies that target the cGAS-STING pathway

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway detects cytoplasmic DNA, triggering innate immune responses like Type-1 interferon production.
• Emerging research implicates the cGAS-STING pathway in various stages of the cancer-immunity cycle (CIC), potentially modulating antitumor immune responses.
• STING agonists are being investigated for cancer immunotherapy, with combination therapies showing promise in preclinical and clinical studies.

Purpose of the Study:

• To comprehensively review the multifaceted role of the cGAS-STING pathway across all phases of the cancer-immunity cycle.
• To focus on the strategic application of STING agonists in combination immunotherapy regimens for cancer treatment.
• To identify and discuss the current challenges and unsolved problems in developing effective STING-based combination therapies.

Main Methods:

• Literature review of scientific publications on the cGAS-STING pathway, cancer immunity, and immunotherapy.
• Analysis of preclinical and clinical trial data concerning STING agonists and combination therapies.
• Synthesis of information to elucidate the pathway's role in CIC and its therapeutic potential.

Main Results:

• The cGAS-STING pathway plays a dual role in cancer immunity, capable of both promoting and suppressing antitumor immune responses depending on the context.
• STING agonists can enhance the efficacy of various cancer immunotherapies by modulating the tumor microenvironment and immune cell infiltration.
• Significant challenges persist in optimizing combination strategies, including patient selection, dosing, and managing potential toxicities.

Conclusions:

• The cGAS-STING pathway is a critical regulator of antitumor immunity and a promising target for novel cancer immunotherapies.
• Combination immunotherapy strategies involving STING agonists hold significant potential but require careful consideration of the CIC and overcoming current therapeutic hurdles.
• Further research is needed to refine patient stratification and combination regimens for maximizing the clinical benefit of STING-targeted therapies.